
    
      Subjects with age-related macular degeneration who meet inclusion and exclusion criteria will
      be randomized to receive monthly intravitreal injections of ranibizumab (LucentisÂ®) with
      either Squalamine Lactate Ophthalmic solution 0.2% or placebo eye drops twice a day for 6
      months. Subjects will be evaluated with clinical and imaging techniques.
    
  